Earlier this month, the Eastern European nation of Hungary’s National Institute of Pharmacy and the European Medicines Agency authorized a clinical trial using Merck’s Stromectol, a brand of ivermectin in a clinical trial targeting mild COVID-19 cases here. The sponsor of this study now, Meditop Pharmaceutical Ltd., targets 70 participants for this randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ivermectin in asymptomatic and mild severity COVID-19 patients. It is also supported by contract research organization (CRO) Cortex Pharma Services. Conducted at three (3) trial site locations, the study is planned to commence for a few months and occurs in the middle of the worst pandemic spike this nation has yet experienced. Hungary’s rate of COVID-19 infection has doubled since its worst spike in November due to the UK variant of SARS-CoV-2.
forrás: 